| 000 | 01599 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250516082955.0 | ||
| 264 | 0 | _c20131017 | |
| 008 | 201310s 0 0 eng d | ||
| 022 | _a1601-0825 | ||
| 024 | 7 |
_a10.1111/j.1601-0825.2012.01911.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPatel, S | |
| 245 | 0 | 0 |
_aNon-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines. _h[electronic resource] |
| 260 |
_bOral diseases _cOct 2012 |
||
| 300 |
_a625-32 p. _bdigital |
||
| 500 | _aPublication Type: Evaluation Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 |
_aBisphosphonate-Associated Osteonecrosis of the Jaw _xpathology |
| 650 | 0 | 4 | _aDenosumab |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aJaw Diseases _xchemically induced |
| 650 | 0 | 4 |
_aOsteonecrosis _xchemically induced |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 | _aTerminology as Topic |
| 700 | 1 | _aChoyee, S | |
| 700 | 1 | _aUyanne, J | |
| 700 | 1 | _aNguyen, A L | |
| 700 | 1 | _aLee, P | |
| 700 | 1 | _aSedghizadeh, P P | |
| 700 | 1 | _aKumar, S K S | |
| 700 | 1 | _aLytle, J | |
| 700 | 1 | _aShi, S | |
| 700 | 1 | _aLe, A D | |
| 773 | 0 |
_tOral diseases _gvol. 18 _gno. 7 _gp. 625-32 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1601-0825.2012.01911.x _zAvailable from publisher's website |
| 999 |
_c21625459 _d21625459 |
||